

Special Issue

PI3K: From Basic Science to Clinical Translation

Message from the Guest Editor

This Special Issue focuses on new functions and/or new discoveries in the regulation of phosphoinositide kinases and phosphatases. It encompasses the functions of inositol lipids and their molecular species, the consequences of a deregulation of phosphoinositide metabolism in human diseases, and the drugs that have been generated to interfere with their function in disease. Basic science investigations continue to provide new insight into molecular medicine and clinical and translational sciences, while good progress has been achieved in PI3K pathway drug development, with several PI3K inhibitors now approved for oncology and several others in the approval and registration pipeline.

Pharmaceuticals invites both reviews and original articles highlighting the molecular basis of PI3K in health and disease as well as opportunities for, and the development of, new therapeutics, quantitative diagnostic/prognostics, and strategies for targeting the PI3K pathway.

Guest Editor

Prof. Dr. Stephen Ward

Centre for Therapeutic Innovation, Leukocyte Biology Laboratory, Life Sciences Department, University of Bath, Claverton Down, Bath BA2 7AY, UK

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/45541

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)